MNOV, US58468P2065

MediciNova reports mixed MN-001 results. Analysts give MediciNova stock a Moderate Buy rating

Published on 10/16/2026 at 01:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

A 40-patient study missed primary endpoints on October 12, 2026. Analysts set a USD 7.75 target for MediciNova stock, with ALS data due by year-end.

Clinical results and analyst view

MediciNova reported mixed MN-001 findings from a 40-patient trial on October 12, 2026.
COMBAT-ALS enrolled 234 participants before its double-blind phase reached its final patient visit on September 24, 2026.
MediciNova had a USD 71.4 million market capitalization as of October 15, 2026.

MNOV, US58468P2065, Illustration mit AI erstellt.

MediciNova (ISIN US58468P2065) said on October 12, 2026 that its 40-patient Phase 2 MN-001 study produced positive signals but did not achieve statistical significance on its primary endpoints. The update keeps attention on the company's planned ALS readout and the wide gap between its market value and analyst targets.

According to GlobeNewswire on October 12, 2026, the randomized, double-blind trial evaluated MN-001 over 24 weeks in patients with nonalcoholic fatty liver disease and elevated triglycerides linked to type 2 diabetes. HDL cholesterol and HDL particle concentration improved significantly versus placebo, while reductions in triglycerides, liver fat and body weight at 24 weeks did not reach statistical significance.

Analysts keep a bullish view

MarketBeat reported on October 9, 2026 that four of seven analysts rated MediciNova a Buy and one rated it a Strong Buy, producing a Moderate Buy consensus and an average 12-month target of USD 7.75. Roth Capital Partners initiated coverage with a Buy rating and a USD 6.00 target on September 17, 2026.

The target spread reflects a market still pricing the company primarily on future clinical milestones. MediciNova's latest reported second-quarter 2026 revenue was USD 0.46 million, while its adjusted loss per share was USD 0.05, compared with a USD 0.06 consensus loss, according to MarketBeat.

Three milestones shape the timeline

On September 24, 2026, MediciNova completed the last patient visit in the double-blind portion of COMBAT-ALS, a Phase 2b/3 study involving 234 participants, according to MediciNova. On October 6, 2026, the company announced management participation in the Maxim Growth Summit from October 12 to October 14, according to GlobeNewswire. On October 12, 2026, the company detailed the 40-patient MN-001 findings.

When is the next milestone?

MediciNova said on September 24, 2026 that the final patient visit for the full COMBAT-ALS study is expected in March 2027, while topline results from the double-blind portion are expected by the end of 2026. The next dated milestone is therefore March 2027, with the year-end readout arriving first.

Market value stays tied to trial risk

MediciNova was last quoted at USD 1.45 on the Nasdaq on October 15, 2026 at 4:00 p.m. ET in after-hours data. Its market capitalization was USD 71.4 million, and its 52-week range was USD 1.17 to USD 3.90 on the same date. The valuation remains sensitive to whether COMBAT-ALS can deliver a stronger clinical signal than MN-001.